Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Deal Size: $17.8 million Upfront Cash: Undisclosed
Deal Type: Collaboration March 02, 2021
Under the terms of the agreement, Oscotec is entitled to gain exclusive global rights for further development and commercialization of Beactica's programme.